Suchergebnisse - "Krebs-Brown, Axel"

PubPharm (36)

1

Asia-Inclusive Global Development of Enpatoran : Results of an Ethno-Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

enthalten in: Clinical pharmacology and therapeutics | 2024

von Klopp-Schulze, L. | Gopalakrishnan, S. | Yalkinoglu, �. | +10

2

Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers : Effect of food and pharmacokinetics of an oral suspension

enthalten in: Clinical and translational science | 2023

von Becker, A. | Krebs-Brown, A. | Vetter, C. | +4

3

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates

enthalten in: Investigational new drugs | 2023

von Yalkinoglu, �. | Becker, A. | Krebs-Brown, A. | +9

4

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates

enthalten in: Investigational new drugs | 2023

von Yalkinoglu, �. | Becker, A. | Krebs-Brown, A. | +9

5

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates

enthalten in: Investigational new drugs | 2023

von Yalkinoglu, �. | Becker, A. | Krebs-Brown, A. | +9

6

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates

enthalten in: Investigational new drugs | 2023

von Yalkinoglu, �. | Becker, A. | Krebs-Brown, A. | +9

7

Phase I crossover study of DNA‐protein kinase inhibitor peposertib in healthy volunteers : Effect of food and pharmacokinetics of an oral suspension

enthalten in: Clinical and Translational Science | 2023

von Becker, A. | Krebs‐Brown, A. | Vetter, C. | +4

8

Comment on : "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"

enthalten in: Clinical pharmacokinetics | 2020

von Krebs-Brown, A. | Munafo, A. | Gaikwad, S. | +2

CommentOn: Clin Pharmacokinet. 2020 Jan;59(1):1-5. - PMID 31432471

9

Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

enthalten in: Clinical pharmacokinetics | 2019

von Krebs-Brown, A. | Munafo, A. | Gaikwad, S. | +2

10

Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

enthalten in: Clinical pharmacokinetics | 2019

von Krebs-Brown, A. | Munafo, A. | Gaikwad, S. | +2